| Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. | |
| | |
MedLine Citation:
|
PMID: 14727929 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
It has been clearly shown that lowering low density lipoprotein-cholesterol (LDL-C) [most often with an HMG-CoA reductase inhibitor] decreases the risk of a cardiovascular event. However, this risk reduction was, at most, 35% in clinical trials, meaning that many events could not be prevented. Moreover, reaching target lipid values as recommended by the current guidelines is often difficult, mainly in high-risk situations such as secondary prevention or type 2 diabetes mellitus. As the two main classes of lipid-lowering drugs (HMG-CoA reductase inhibitors and fibric acid derivatives) have complementary effects on lipid parameters, it seems logical to combine both treatments particularly in patients with combined hyperlipidemia. In fact, combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative induces a further decrease in LDL-C levels compared with monotherapy and improves other lipid values such as high density lipoprotein-cholesterol (HDL-C) and triglyceride (TG) levels. Unfortunately, there are currently no available randomized, prospective clinical data on the reduction of the incidence of cardiovascular events with such a combination. This is mainly because the use of HMG-CoA reductase inhibitor and fibric acid derivative combinations was initially described as dangerous. It is true that such a combination increases the risk of muscle toxicity that already exists with monotherapy. Muscle toxicity can eventually lead to life-threatening rhabdomyolysis and some precautions of use are required; however, the risk seems actually lower than what has been initially reported. The use of combined therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative requires the respect of some rules such as avoiding the prescription in patients with concomitant conditions like renal failure and avoiding the use of gemfibrozil as a fibric acid derivative in such a combination. It is now imperative to design clinical trials to determine the clinical efficacy and precise safety of this combined treatment especially in patients with abnormalities in every parameter of the lipid triad (LDL, HDL and TG) and a high vascular risk such as patients with type 2 diabetes mellitus. |
| | |
Authors:
|
Michel Farnier |
Related Documents
:
|
2155299 - Lipoproteins of varicella-zoster virus. 2306509 - High-resolution electron density profiles reveal influence of fatty acids on bilayer st... 20020949 - The relationship between lipid peroxidation and ldl desialylation in experimental ather... 8977049 - Fat cells. 175849 - Characterization of the ehrlich ascites tumor plasma lipoproteins. 7142509 - Pulmonary edema: a ct study of regional changes in lung density following oleic acid in... 6713959 - Biochemical studies on the use of sodium hyaluronate in the anterior eye segment. ii. t... 1367779 - Comparison of the amino acid sequences of the lectins from seeds of dioclea lehmanni an... 16130769 - Continuous, on-line monitoring of haloacetic acids via membrane extraction. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of cardiovascular drugs : drugs, devices, and other interventions Volume: 3 ISSN: 1175-3277 ISO Abbreviation: Am J Cardiovasc Drugs Publication Date: 2003 |
Date Detail:
|
Created Date: 2004-01-19 Completed Date: 2008-10-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100967755 Medline TA: Am J Cardiovasc Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 169-78 Citation Subset: IM |
Affiliation:
|
Point Médical, Rond Point de la Nation, Dijon, France. mfarnier@ipac.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
administration & dosage* Cholesterol, HDL / blood Cholesterol, LDL / blood Drug Therapy, Combination Gemfibrozil / administration & dosage* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage* Hyperlipidemias / blood, drug therapy* Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Triglycerides; 25812-30-0/Gemfibrozil |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Risk of suicide in users of cardiovascular drugs: a review of the epidemiological evidence.
Next Document: Cost effectiveness of HMG-CoA reductase inhibitors in the management of coronary artery disease: the...